Kailera Therapeutics, Inc.
NASDAQ:KLRABiotechnology
+$0.51 today
- Market cap
- $1.53B
- Beta
- 0.00
Volume 0.42M
Average 0.80M
KLRA Interest Income
Income earned on cash, deposits, and investments held by the company.
Kailera Therapeutics, Inc.NASDAQ: KLRA
Interest Income · Q2 FY2026 · quarter ended Jun 2026
Interest income of $9.99M in Q2 FY2026
Q2 FY2026 interest income was $9.99M.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Income history
USD · from the income statement
- Latest · FY2025
- 11.05M USD
- Year-over-year change
- —
| Period | Period end | Interest Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 11.05M | — |
Interest Income vs competitors
How KLRA compares with its peers on the latest reported figures
- KLRA's FY2025 interest income of $11.05M is the 5th highest of the 10 companies compared; the peer median is $8.9M.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $25.15M | -39.1% | +176.8% | — | |
| LTM Jun 2026 | $23.03M | -1.3% | — | 323.5% | |
| LTM Mar 2026 | $16.15M | +417.4% | -12.8% | — | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $12.64M | +4.9% | +204.2% | 122.5% |
KLRAKailera Therapeutics, Inc. | FY2025 | $11.05M | — | — | — |
| LTM Mar 2026 | $8.9M | +23.5% | +38.0% | 24713.9% | |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | $4.16M | -60.0% | +210.0% | — |
| LTM Mar 2026 | $2.38M | +30.8% | +74.5% | 6.5% | |
| LTM Mar 2026 | $1.84M | -55.1% | +1.0% | — | |
| LTM Mar 2026 | $1.63M | -54.1% | +24.6% | — | |
| Peer median (excluding KLRA) | $8.9M | -1.3% | +56.2% | 223.0% | |
Competitors are the stored peer set for KLRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2025 Dec 2025 |
|---|---|
| Revenue | 0 |
| Cost of Revenue | 0 |
| Gross Profit | 0 |
| Gross Margin | — |
| Research & Development | 109.11M |
| Selling, General & Admin | 49.23M |
| Operating Expenses | 158.34M |
| Depreciation & Amortization | 310K |
| EBITDA | (158.03M) |
| EBITDA Margin | — |
| Operating Income | (158.34M) |
| Operating Margin | — |
| Interest Income | 11.05M |
| Interest Expense | 0 |
| Other Income / Expenses | 9.39M |
| Income Before Tax | (148.96M) |
| Pre-Tax Margin | — |
| Income Tax Expense | 0 |
| Net Income | (148.96M) |
| Net Margin | — |
| EPS (Basic) | (1.26) |
| EPS (Diluted) | (1.26) |
| Weighted Avg Shares | 117.95M |
| Weighted Avg Shares (Diluted) | 117.95M |
Kailera Therapeutics, Inc.
NASDAQ:KLRA
Intrinsic Alpha fair value
Locked
Current Price
$11.79
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.